News stories about Alder BioPharmaceuticals (NASDAQ:ALDR) have been trending somewhat positive on Sunday, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Alder BioPharmaceuticals earned a news impact score of 0.09 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.2552014987148 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

Alder BioPharmaceuticals (NASDAQ ALDR) traded up 5.08% during trading on Friday, hitting $9.30. The stock had a trading volume of 1,416,650 shares. The company’s 50-day moving average is $11.56 and its 200 day moving average is $18.22. Alder BioPharmaceuticals has a 52 week low of $8.80 and a 52 week high of $36.48. The firm’s market cap is $629.73 million.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.67) by $0.19. The company had revenue of $0.68 million during the quarter. During the same quarter last year, the firm earned ($0.79) earnings per share. The business’s quarterly revenue was up 518.2% compared to the same quarter last year. Equities analysts expect that Alder BioPharmaceuticals will post ($5.82) EPS for the current fiscal year.

ALDR has been the subject of several recent research reports. Credit Suisse Group downgraded shares of Alder BioPharmaceuticals from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $30.00 to $17.00 in a research report on Wednesday, June 28th. Zacks Investment Research raised shares of Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Tuesday, July 11th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $51.00 price objective on shares of Alder BioPharmaceuticals in a research report on Wednesday, June 28th. ValuEngine raised shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 20th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $47.00 price objective on shares of Alder BioPharmaceuticals in a research report on Wednesday, June 28th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $32.92.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Alder BioPharmaceuticals (NASDAQ:ALDR) Stock Price” was reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at

In other Alder BioPharmaceuticals news, Director Stephen M. Dow purchased 25,000 shares of the company’s stock in a transaction on Tuesday, July 18th. The shares were bought at an average cost of $10.00 per share, with a total value of $250,000.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 10.60% of the company’s stock.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Insider Buying and Selling by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with's FREE daily email newsletter.